Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

Table 7 Effect of MicroRNA for RAS wild-type patients, according to treatment

Biomarker	Study	Subgroup	N	PFS			OS			ORR
				Median, months	HR (95% CI)	P value	Median, months	HR (95% CI)	P value	Rate, %	Odds ratio (95% CI)	P value
*MiR-31-3p*
	PICCOLO
		Panitumumab ± Irinotecan (N = 188)				0.018			0.0012			NR
		Int: Low	NR	NR	1.60		NR	1.58		NR	NR
		High: Low	NR	NR	1.60		NR	2.03		NR	NR
	FIRE-3
		Cetuximab/Bevacizumab ± FOLFIRI (N = 340)			1.11 (0.85, 1.45)	0.43		1.43 (1.05, 1.96)	0.02		NR	NR
		High (≥ a prespecified cutoff (1.36))	111	7.8			20.3			NR
		Low (< a prespecified cutoff (1.36))	229	11.1			30.3			NR
		Cetuximab/Bevacizumab ± FOLFIRI (N = 340)
		Log miR-31-3p	340	NR	1.15 (1.05, 1.25)	< 0.01	NR	1.26 (1.13, 1.40)	< 0.01	NR	NR	NR
	New EPOC
		Cetuximab + oxaliplatin/irinotecan plus fluorouracil (N = 78)			2.00 (1.00, 4.20)	0.50		1.10 (0.40, 3.00)	0.85		0.92 (0.33, 2.54)	0.874
		Mid + High (mid + high tertiles)	51	12.3			NR			68.6
		Low (low tertile)	27	20.3			NR			70.4
		Oxaliplatin/irinotecan plus fluorouracil (N = 71)			0.90 (0.40, 2.00)	0.79		0.70 (0.20, 2.90)	0.62		0.69 (0.25, 1.92)	0.473
		Mid + High (mid + high tertiles)	48	NR			NR			56.3
		Low (low tertile)	23	NR			NR			65.2
		Cetuximab + oxaliplatin/irinotecan plus fluorouracil (N = 62)			1.20 (0.98, 1.48)	0.035		NR	NR		NR	NR
		Log2 miR-31-3p	62	NR			NR			NR
		Oxaliplatin/irinotecan plus fluorouracil (N = 63)			0.96 (0.75, 1.23)	0.36		NR	NR		NR	NR
		Log2 miR-31-3p	63	NR			NR			NR

ISSN: 1471-2407